New injection aims to tame autoimmune attack in Sjogren's patients

NCT ID NCT05350072

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new drug called ianalumab can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 276 participants will receive either the drug or a placebo as a monthly injection for nearly a year. Researchers will measure changes in overall disease severity, dryness, pain, and fatigue to see if the treatment is effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Altoona Center for Clin Res

Duncansville, Pennsylvania, 16635, United States
Baylor College Of Medicine

Houston, Texas, 77030, United States
Carolina Arthritis Associates

Wilmington, North Carolina, 28401, United States
Houston Rheumatology & Arthrit

Katy, Texas, 77494, United States
Indiana Univ School of Dentistry

Indianapolis, Indiana, 46202, United States
Medvin Clinical Research

Van Nuys, California, 91405, United States
Metroplex Clinical Research

Dallas, Texas, 75231, United States
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Stockerau, 2000, Austria
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Vitória, Espírito Santo, 29055 450, Brazil
Novartis Investigative Site

Juiz de Fora, Minas Gerais, 36010 570, Brazil
Novartis Investigative Site

Ribeirão Preto, São Paulo, 14048-900, Brazil
Novartis Investigative Site

São Paulo, 01409-902, Brazil
Novartis Investigative Site

Santiago, Santiago Metropolitan, 7500571, Chile
Novartis Investigative Site

Santiago, Santiago Metropolitan, 7500710, Chile
Novartis Investigative Site

Guangzhou, Guangdong, 510630, China
Novartis Investigative Site

Shenzhen, Guangdong, 518020, China
Novartis Investigative Site

Wuhan, Hubei, 430030, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014010, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010050, China
Novartis Investigative Site

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site

Shenyang, Liaoning, 110011, China
Novartis Investigative Site

Linyi, Shandong, 276000, China
Novartis Investigative Site

Taiyuan, Shanxi, 030000, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Brno, 638 00, Czechia
Novartis Investigative Site

Prague, 148 00, Czechia
Novartis Investigative Site

Uherské Hradiště, 686 01, Czechia
Novartis Investigative Site

Caen, 14033, France
Novartis Investigative Site

Dijon, 21000, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Marseille, 13005, France
Novartis Investigative Site

Paris, 75010, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Saint-Priest-en-Jarez, 42270, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Erlangen, 91056, Germany
Novartis Investigative Site

Gommern, 39245, Germany
Novartis Investigative Site

Ludwigshafen, 67063, Germany
Novartis Investigative Site

Guatemala City, 01009, Guatemala
Novartis Investigative Site

Guatemala City, 01010, Guatemala
Novartis Investigative Site

Guatemala City, 01011, Guatemala
Novartis Investigative Site

Quetzaltenango, 9001, Guatemala
Novartis Investigative Site

Vilnius, 08406, Lithuania
Novartis Investigative Site

Guadalajara, Jalisco, 44650, Mexico
Novartis Investigative Site

Mexico City, Mexico City, 06700, Mexico
Novartis Investigative Site

Wroclaw, Lower Silesian Voivodeship, 52-210, Poland
Novartis Investigative Site

Bydgoszcz, 85-168, Poland
Novartis Investigative Site

Krakow, 30-002, Poland
Novartis Investigative Site

Lublin, 20-090, Poland
Novartis Investigative Site

Braga, 4710243, Portugal
Novartis Investigative Site

Guarda, 6301-858, Portugal
Novartis Investigative Site

Lisbon, 1050-034, Portugal
Novartis Investigative Site

Lisbon, 1349-019, Portugal
Novartis Investigative Site

Lisbon, 1649-035, Portugal
Novartis Investigative Site

Singapore, S308433, Singapore
Novartis Investigative Site

Gwangju, 61469, South Korea
Novartis Investigative Site

Seoul, 06591, South Korea
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site

Bilbao, Bizkaia, 48013, Spain
Novartis Investigative Site

A Coruña, 15006, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Ankara, Bilkent Cankaya, 06800, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site

Kocaeli, 41380, Turkey (Türkiye)
Ochsner Health System

Baton Rouge, Louisiana, 70809, United States
Precision Comprehensive Research

Colleyville, Texas, 76034, United States
Prisma Health

Columbia, South Carolina, 29203, United States
STAT Research Inc

Dayton, Ohio, 45402, United States
The John Hopkins Jerome L Greene Sjogren

Baltimore, Maryland, 21224, United States
West Broward Rheumatology Associates Inc

Tamarac, Florida, 33321, United States
Winthrop University Hospital

Mineola, New York, 11501, United States

Conditions

Explore the condition pages connected to this study.

SJOGREN SYNDROME